Supplementary Figure 4 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Ghassan K. Abou-Alfa,Susan M. Geyer,Andrew B. Nixon,Federico Innocenti,Qian Shi,Priya Kumthekar, Sawyer Jacobson,Imane El Dika,Amin Yaqubie, Juan Lopez, Binhui Huang,Yi-Wei Tang,Yujia Wen,Lawrence H. Schwartz,Anthony B. El-Khoueiry,Jennifer J. Knox,Lakshmi Rajdev,Monica M. Bertagnolli, Jeffrey A. Meyerhardt, Eileen M. O'Reilly,Alan P. Venook

crossref（2024）

引用 0|浏览6

暂无评分

摘要

Supplementary Figure 4. Kaplan-Meier curves for the overall survival distributions for patients who have detectable (HCV-D) vs. undetectable (HCV-UN) HCV titer levels on their first evaluated sample, by treatment arm.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要